Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.70 |
| ▸ | PRKCA | P17252 | 4/20 | 0.69 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.69 |
| ▸ | PRKCG | P05129 | 3/20 | 0.69 |
| ▸ | PRKCB | P05771 | 3/20 | 0.69 |
| ▸ | PRKCH | P24723 | 3/20 | 0.69 |
| ▸ | PRKCI | P41743 | 3/20 | 0.69 |
| ▸ | PRKCE | Q02156 | 3/20 | 0.69 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.69 |
| ▸ | PRKCZ | Q05513 | 3/20 | 0.69 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.69 |
| ▸ | PRKD1 | Q15139 | 3/20 | 0.69 |
| ▸ | USP2 | O75604 | 2/20 | 0.69 |
| ▸ | TP53 | P04637 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18628825 | 1.00 | PTGS2 (0.70) | PTGS2PRKCAPRKD3PRKCGPRKCB | |
| SCHEMBL18399996 | 1.00 | PTGS2 (0.70) | PTGS2PRKCAPRKD3PRKCGPRKCB | |
| SCHEMBL17367889 | 1.00 | PTGS2 (0.70) | PTGS2PRKCAPRKD3PRKCGPRKCB | |
| SCHEMBL18687212 | 1.00 | PTGS2 (0.70) | PTGS2PRKCAPRKD3PRKCGPRKCB | |
| SCHEMBL18680592 | 1.00 | PTGS2 (0.70) | PTGS2PRKCAPRKD3PRKCGPRKCB | |
| SCHEMBL29762786 | 0.92 | PRKCA (0.79) | PTGS2PRKCAPRKD3PRKCGPRKCB | |
| SCHEMBL19344745 | 0.92 | PRKCA (0.79) | PTGS2PRKCAPRKD3PRKCGPRKCB | |
| SCHEMBL1537765 | 0.92 | PRKCA (0.79) | PTGS2PRKCAPRKD3PRKCGPRKCB | |
| SCHEMBL18399927 | 0.90 | PTGS2 (0.64) | PTGS2PRKCAPRKD3PRKCGPRKCB | |
| SCHEMBL15423106 | 0.90 | PTGS2 (0.64) | PTGS2PRKCAPRKD3PRKCGPRKCB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230248684-A1 | COMPOSITIONS AND METHODS FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) AND INFLAMMATORY DISORDERS CAUSED BY CORONAVIRUSES AND OTHER RESPIRATORY PATHOGENS OR AGENTS THAT MEDIATE PULMONARY INJURY, INFLAMMATION OR ACUTE RESPIRATORY DISTRESS, AND RELATED COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING HUMAN SARS CORONAVIRUS INFECTION, COVID-19 DISEASE AND RELATED SYMPTOMS | PHOR-MED, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20170096386-A1 | Compositions And Methods Of Use Of Phorbol Esters For Treatment of Stroke | CHANG RICHARD L (US) | 2017-04-06 | — | — | US | disclosed |
| US-9550722-B2 | Compositions and methods of use of phorbal esters for the treatment of stroke | BIOSUCCESS BIOTECH CO. LTD. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550722-B2 | Compositions and methods of use of phorbal esters for the treatment of stroke | BIOSUCCESS BIOTECH CO. LTD. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9533938-B2 | Compositions and methods of use of phorbol esters for the treatment of stroke | BIOSUCCESS BIOTECH CO., LTD. (US) | 2017-01-03 | — | — | US | disclosed |
| US-20160332955-A9 | Compositions And Methods Of Use Of Phorbol Esters In The Treatment Of Neoplasms | BIOSUCCESS BIOTECH CO. LTD. (US) | 2016-11-17 | — | — | US | disclosed |
| US-20160332955-A9 | Compositions And Methods Of Use Of Phorbol Esters In The Treatment Of Neoplasms | BIOSUCCESS BIOTECH CO. LTD. (US) | 2016-11-17 | — | — | US | disclosed |
| US-20160237020-A9 | Compositions And Methods Of Use Of Phorbol Esters For the Treatment Of Stroke | BIOSUCCESS BIOTECH CO. LTD. (US) | 2016-08-18 | — | — | US | disclosed |
| US-20160237020-A9 | Compositions And Methods Of Use Of Phorbol Esters For the Treatment Of Stroke | BIOSUCCESS BIOTECH CO. LTD. (US) | 2016-08-18 | — | — | US | disclosed |
| US-20150374648-A1 | Compositions And Methods Of Use Of Phorbol Esters In The Treatment Of Neoplasms | CHANG RICHARD L (US) | 2015-12-31 | — | — | US | disclosed |
| US-20150071908-A1 | Compositions And Methods Of Use Of Phorbol Esters For the Treatment Of Stroke | BIOSUCCESS BIOTECH CO. LTD. (US) | 2015-03-12 | — | — | US | disclosed |
| US-20150071908-A1 | Compositions And Methods Of Use Of Phorbol Esters For the Treatment Of Stroke | BIOSUCCESS BIOTECH CO. LTD. (US) | 2015-03-12 | — | — | US | disclosed |
| US-20150072960-A1 | Compositions And Methods Of Use Of Phorbol Esters In The Treatment Of Neoplasms | BIOSUCCESS BIOTECH CO. LTD. (US) | 2015-03-12 | — | — | US | disclosed |
| US-20150072960-A1 | Compositions And Methods Of Use Of Phorbol Esters In The Treatment Of Neoplasms | BIOSUCCESS BIOTECH CO. LTD. (US) | 2015-03-12 | — | — | US | disclosed |
| US-20140140979-A1 | Compositions And Methods Of Use of Phorbol Esters For Treatment of Stroke | BIOSUCCESS BIOTECH CO. LTD. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140140979-A1 | Compositions And Methods Of Use of Phorbol Esters For Treatment of Stroke | BIOSUCCESS BIOTECH CO. LTD. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140018329-A1 | COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS IN THE TREATMENT OF NEOPLASMS | BIOSUCCESS BIOTECH CO., LTD. (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140018329-A1 | COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS IN THE TREATMENT OF NEOPLASMS | BIOSUCCESS BIOTECH CO., LTD. (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140011873-A1 | COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS FOR THE TREATMENT OF STROKE | BIOSUCCESS BIOTECH CO., LTD (US) | 2014-01-09 | — | — | US | disclosed |
| US-20140011873-A1 | COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS FOR THE TREATMENT OF STROKE | BIOSUCCESS BIOTECH CO., LTD (US) | 2014-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011873-A1 | COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS FOR THE TREATMENT OF STROKE | PMAIP1, EBP, PLAT | PTGS2 258/4885PRKCA 13/4885PRKD3 460/4885 |
| US-20160332955-A9 | Compositions And Methods Of Use Of Phorbol Esters In The Treatment Of Neoplasms | PMAIP1, MYD88, HRAS | PTGS2 569/4885PRKCA 15/4885PRKD3 206/4885 |
| US-20150374648-A1 | Compositions And Methods Of Use Of Phorbol Esters In The Treatment Of Neoplasms | PMAIP1, MYD88, HRAS | PTGS2 569/4885PRKCA 15/4885PRKD3 206/4885 |
| US-20140018329-A1 | COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS IN THE TREATMENT OF NEOPLASMS | PMAIP1, MYD88, HRAS | PTGS2 569/4885PRKCA 15/4885PRKD3 206/4885 |
| US-20140140979-A1 | Compositions And Methods Of Use of Phorbol Esters For Treatment of Stroke | PMAIP1, PLAT, EBP | PTGS2 229/4885PRKCA 15/4885PRKD3 443/4885 |
| US-20160237020-A9 | Compositions And Methods Of Use Of Phorbol Esters For the Treatment Of Stroke | PMAIP1, EBP, PLAT | PTGS2 258/4885PRKCA 13/4885PRKD3 460/4885 |
| US-20170096386-A1 | Compositions And Methods Of Use Of Phorbol Esters For Treatment of Stroke | PMAIP1, PLAT, EBP | PTGS2 229/4885PRKCA 15/4885PRKD3 443/4885 |
| US-20230248684-A1 | COMPOSITIONS AND METHODS FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) AND INFLAMMATORY DISORDERS CAUSED BY CORONAVIRUSES AND OTHER RESPIRATORY PATHOGENS OR AGENTS THAT MEDIATE PULMONARY INJURY, INFLAMMATION OR ACUTE RESPIRATORY DISTRESS, AND RELATED COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING HUMAN SARS CORONAVIRUS INFECTION, COVID-19 DISEASE AND RELATED SYMPTOMS | MAVS, ACE2, CCL11 | PTGS2 29/4885PRKCA 16/4885PRKD3 716/4885 |
| US-20150071908-A1 | Compositions And Methods Of Use Of Phorbol Esters For the Treatment Of Stroke | PMAIP1, EBP, PLAT | PTGS2 258/4885PRKCA 13/4885PRKD3 460/4885 |
| US-20150072960-A1 | Compositions And Methods Of Use Of Phorbol Esters In The Treatment Of Neoplasms | PMAIP1, MYD88, HRAS | PTGS2 569/4885PRKCA 15/4885PRKD3 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.